The United Kingdom

Following the 1990 NHS reforms, health technology assessment (HTA) in the United Kingdom has become the largest and most developed of the NHS Research and Development (R&D) Strategy. A strategy that was created to promote a knowledge-based health service with a strong research infrastructure and the capacity to critically review its own needs. HTA in the UK has a formal system for setting assessment priorities involving widespread consultation within the NHS, and a National Co-ordinating Centre for Health Technology Assessment. A hallmark of the UK HTA program is the strong public participation.

Ebola threat intensifies in DR Congo

The Ebola outbreak in the Democratic Republic of Congo is becoming increasingly serious, after it was confirmed that there was a case of a person infected by the virus in the city of Mbandaka. The city has a population of approximately one million people and sits on the Congo River, […]

Study finds Herceptin use can be halved

IMAGE: Tiffany Trojca A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just as effective after a reduced treatment period of six months compared with the standard 12 months, in women with HER2 positive early-stage breast cancer. This is a […]

Living with an undiagnosed condition

Samantha O’Shea explains some of the challenges she faces caring for her son, Ethan, who lives with a debilitating but undiagnosed condition. When did you first notice that Ethan was developing in a way that caused concern? It would have been when he was about eight or nine months old, […]

Europe expands approved indication of Amgen's Repatha in cardiovascular disease

Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels in adult patients with established atherosclerotic cardiovascular disease, such as myocardial infarction, stroke or peripheral arterial disease. The EC’s […]

Roche gets NICE approval for advanced bladder cancer

Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment is still gaining ground with regulators for its initial treatment focus in bladder cancer. NICE has announced that the immunotherapy will be made available for patients with advanced bladder cancer […]

DIA: Pharmacovigilance conference

We are in the midst of a breath-taking series of changes in the world of pharmacovigilance, both within Europe and beyond and this has prompted new challenges for all stakeholders. The implementation of the new EudraVigilance system; re-examination of the way we assess and present safety concerns for authorized products; […]